Gisela Gadea-Nogales

Badalona, CT 08916, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications

Characterization of DMPK and MBNL1 expression in cell models of myotonic dystrophy: a platform for drug screening.

Characterization of DMPK and MBNL1 expression in cell models of myotonic dystrophy: a platform for drug screening.

Journal: NAR molecular medicine
Published: March 07, 2025

HDAC11 deficiency improves muscle phenotype in a Duchenne muscular dystrophy murine model by reducing inflammation and fibrosis.

HDAC11 deficiency improves muscle phenotype in a Duchenne muscular dystrophy murine model by reducing inflammation and fibrosis.

Journal: Life sciences
Published: January 22, 2025

HDAC11 deficiency regulates age-related muscle decline and sarcopenia.

HDAC11 deficiency regulates age-related muscle decline and sarcopenia.

Journal: GeroScience
Published: January 03, 2025

Erratum: Immortalized human myotonic dystrophy type 1 muscle cell lines to address patient heterogeneity.

Erratum: Immortalized human myotonic dystrophy type 1 muscle cell lines to address patient heterogeneity.

Journal: iScience
Published: December 30, 2024

Efficacy of MLN9708 (ixazomib) in experimental autoimmune myasthenia gravis and in anti-AChR producing primary thymic cell cultures from myasthenia gravis patients.

Efficacy of MLN9708 (ixazomib) in experimental autoimmune myasthenia gravis and in anti-AChR producing primary thymic cell cultures from myasthenia gravis patients.

Journal: Frontiers in immunology
Published: November 01, 2024

AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action.

AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action.

Journal: Science advances
Published: October 09, 2024

Immortalized human myotonic dystrophy type 1 muscle cell lines to address patient heterogeneity.

Immortalized human myotonic dystrophy type 1 muscle cell lines to address patient heterogeneity.

Journal: iScience
Published: July 10, 2023

Low aerobic capacity in McArdle disease: A role for mitochondrial network impairment?

Low aerobic capacity in McArdle disease: A role for mitochondrial network impairment?

Journal: Molecular metabolism
Published: October 07, 2022

An Integrative Analysis of DNA Methylation Pattern in Myotonic Dystrophy Type 1 Samples Reveals a Distinct DNA Methylation Profile between Tissues and a Novel Muscle-Associated Epigenetic Dysregulation.

An Integrative Analysis of DNA Methylation Pattern in Myotonic Dystrophy Type 1 Samples Reveals a Distinct DNA Methylation Profile between Tissues and a Novel Muscle-Associated Epigenetic Dysregulation.

Journal: Biomedicines
Published: April 22, 2022

Long-Term Exercise Intervention in Patients with McArdle Disease: Clinical and Aerobic Fitness Benefits.

Long-Term Exercise Intervention in Patients with McArdle Disease: Clinical and Aerobic Fitness Benefits.

Journal: Medicine and science in sports and exercise
Published: March 23, 2022

Senescence plays a role in myotonic dystrophy type 1.

Senescence plays a role in myotonic dystrophy type 1.

Journal: JCI insight
Published: February 14, 2022

Erratum to ``Clinical practice guidelines for glycogen storage disease V & VII (McArdle disease and Tarui disease) from an international study group'' [Neuromuscular Disorders 31 (2021) 1296-1310].

Erratum to ``Clinical practice guidelines for glycogen storage disease V & VII (McArdle disease and Tarui disease) from an international study group'' [Neuromuscular Disorders 31 (2021) 1296-1310].

Journal: Neuromuscular disorders : NMD
Published: February 10, 2022
Showing 1-12 of 63

Last Updated: 09/26/2026